Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment-Reference-Cited by-同舟云学术

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment

Published:2012-01 Issue:1 Volume:7 Page:122-127
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Azuma Koichi,Okamoto Isamu,Kawahara Akihiko,Taira Tomoki,Nakashima Kazutaka,Hattori Satoshi,Kinoshita Takashi,Takeda Masayuki,Nakagawa Kazuhiko,Takamori Shinzo,Kuwano Michihiko,Ono Mayumi,Kage Masayoshi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Cancer burden in the year 2000: the global picture;Parkin;Eur J Cancer,2001

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

4. EGF receptor gene mutations are common in lung cancers from “neversmokers” and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc Natl Acad Sci U S A,2004

5. Molecular mechanisms of epidermal growth factor receptor activation and response to gefitinib and other EGFR-targeting drugs;Ono;Clin Cancer Res,2006

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi‐omics differential gene regulatory network inference for lung adenocarcinoma tumor progression biomarker discovery;AIChE Journal;2022-01-18

2. Study of Programmed Death Ligand 1 and EGFR/HER2 Expression in Non-Small-Cell Lung Carcinoma With a Clinicopathological Spectrum;Cureus;2021-07-05

3. Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients;Journal of Thoracic Disease;2019-12

4. Expression of HGF, MET and mutated EGFR in EGFR mutated lung adenocarcinoma and their clinical significance;Translational Cancer Research;2017-08

5. Immunohistochemistry for EGFR Mutation Detection in Non–Small-Cell Lung Cancer;Clinical Lung Cancer;2017-05